254 related articles for article (PubMed ID: 1309872)
1. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents.
Compton DR; Johnson MR; Melvin LS; Martin BR
J Pharmacol Exp Ther; 1992 Jan; 260(1):201-9. PubMed ID: 1309872
[TBL] [Abstract][Full Text] [Related]
2. Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol.
Compton DR; Gold LH; Ward SJ; Balster RL; Martin BR
J Pharmacol Exp Ther; 1992 Dec; 263(3):1118-26. PubMed ID: 1335057
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of agonist-antagonist properties of nitrogen mustard and cyano derivatives of delta 8-tetrahydrocannabinol.
Wiley JL; Compton DR; Gordon PM; Siegel C; Singer M; Dutta A; Lichtman AH; Balster RL; Razdan RK; Martin BR
Neuropharmacology; 1996; 35(12):1793-804. PubMed ID: 9076759
[TBL] [Abstract][Full Text] [Related]
4. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs.
Martin BR; Compton DR; Thomas BF; Prescott WR; Little PJ; Razdan RK; Johnson MR; Melvin LS; Mechoulam R; Ward SJ
Pharmacol Biochem Behav; 1991 Nov; 40(3):471-8. PubMed ID: 1666911
[TBL] [Abstract][Full Text] [Related]
5. Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212.
Fan F; Compton DR; Ward S; Melvin L; Martin BR
J Pharmacol Exp Ther; 1994 Dec; 271(3):1383-90. PubMed ID: 7996450
[TBL] [Abstract][Full Text] [Related]
6. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception.
Welch SP; Dunlow LD; Patrick GS; Razdan RK
J Pharmacol Exp Ther; 1995 Jun; 273(3):1235-44. PubMed ID: 7791096
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs.
Melvin LS; Milne GM; Johnson MR; Subramaniam B; Wilken GH; Howlett AC
Mol Pharmacol; 1993 Nov; 44(5):1008-15. PubMed ID: 8246904
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological evaluation of halogenated delta 8-THC analogs.
Charalambous A; Lin S; Marciniak G; Banijamali A; Friend FL; Compton DR; Martin BR; Makriyannis A
Pharmacol Biochem Behav; 1991 Nov; 40(3):509-12. PubMed ID: 1666915
[TBL] [Abstract][Full Text] [Related]
9. A novel class of potent tetrahydrocannabinols (THCS): 2'-yne-delta 8- and delta 9-THCS.
Ryan W; Singer M; Razdan RK; Compton DR; Martin BR
Life Sci; 1995; 56(23-24):2013-20. PubMed ID: 7776826
[TBL] [Abstract][Full Text] [Related]
10. Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice.
Smith PB; Welch SP; Martin BR
J Pharmacol Exp Ther; 1994 Mar; 268(3):1381-7. PubMed ID: 8138952
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological evaluation of iodo and nitro analogs of delta 8-THC and delta 9-THC.
Martin BR; Compton DR; Semus SF; Lin S; Marciniak G; Grzybowska J; Charalambous A; Makriyannis A
Pharmacol Biochem Behav; 1993 Oct; 46(2):295-301. PubMed ID: 8265683
[TBL] [Abstract][Full Text] [Related]
12. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study.
Oviedo A; Glowa J; Herkenham M
Brain Res; 1993 Jul; 616(1-2):293-302. PubMed ID: 8395305
[TBL] [Abstract][Full Text] [Related]
13. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement.
Lichtman AH; Cook SA; Martin BR
J Pharmacol Exp Ther; 1996 Feb; 276(2):585-93. PubMed ID: 8632325
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the role of the phenolic hydroxyl in cannabinoid activity.
Reggio PH; Seltzman HH; Compton DR; Prescott WR; Martin BR
Mol Pharmacol; 1990 Dec; 38(6):854-62. PubMed ID: 2174506
[TBL] [Abstract][Full Text] [Related]
15. Cannabimimetic properties of ajulemic acid.
Vann RE; Cook CD; Martin BR; Wiley JL
J Pharmacol Exp Ther; 2007 Feb; 320(2):678-86. PubMed ID: 17105826
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
Compton DR; Little PJ; Martin BR; Gilman JW; Saha JK; Jorapur VS; Sard HP; Razdan RK
J Med Chem; 1990 May; 33(5):1437-43. PubMed ID: 2158563
[TBL] [Abstract][Full Text] [Related]
17. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide.
Houser SJ; Eads M; Embrey JP; Welch SP
Brain Res; 2000 Feb; 857(1-2):337-42. PubMed ID: 10700588
[TBL] [Abstract][Full Text] [Related]
18. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide.
Pertwee RG; Stevenson LA; Griffin G
Br J Pharmacol; 1993 Dec; 110(4):1483-90. PubMed ID: 8306090
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the discriminative stimulus properties of delta 9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys.
Gold LH; Balster RL; Barrett RL; Britt DT; Martin BR
J Pharmacol Exp Ther; 1992 Aug; 262(2):479-86. PubMed ID: 1323651
[TBL] [Abstract][Full Text] [Related]
20. The effects of delta 9-tetrahydrocannabinol and other cannabinoids on cAMP accumulation in synaptosomes.
Little PJ; Martin BR
Life Sci; 1991; 48(12):1133-41. PubMed ID: 1848340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]